Circulating endothelial cells and circulating endothelial cell progenitors as surrogate markers for determining response to antiangiogenic agents

Clinical Colorectal Cancer

Volumn 6, Issue 5, 2007, Pages 337-338

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CD146 ANTIGEN; VANDETANIB;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER THERAPY; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM CELL; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; RECTUM CANCER; STEM CELL; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 33847372027     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70260-2     Document Type: Article

References (26)

1. Hurwitz H, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
3. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94(suppl 1):S6 (Abstract #3).
4. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23(16 suppl):1093s (Abstract #4510).
5. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24(18 suppl):930s (Abstract #LBA3).
6. Nikitenko L, Boshoff C. Endothelial cells and cancer. Handb Exp Pharmacol 2006; 176:307-334.
7. Bertolinin F, Shaked Y, Mancuso P, et al. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nature Rev 2006; 6:835-845.
8. Blann AD, Woywodt A, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93:228-235.
9. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7:101-111.
10. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11:3514-3522.
11. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone marrowed-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med 2001; 7:1194-1201.
12. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300:1155-1159.
13. De Palma M, Venneri MA, Roca C, et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nature Med 2003; 9:789-795.
14. Spadaro P, Dottore G, Toscano G, et al. Changes in circulating endothelial cells (CECs) in patients receiving trastuzumab for metastatic breast cancer predict response to treatment. J Clin Oncol 2006; 24(18 suppl):22s (Abstract #579).
15. Raida M, Weiss T, Leo C, et al. Circulating endothelial progenitor cells are inversely correlated with the median oxygen tension in the tumor tissue of patients with cervical cancer. Oncol Rep 2006; 16:597-601.
16. Dome B, Timar J, Dobos J, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 2006; 66:7341-7347.
17. Ho JW, Lau C, Sun CK, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006; 44:836-843.
18. Duda DG, Cohen KS, di Tomaso E, et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24:1449-1453.
19. Stoll BR, Kadambi A, Munn LL, et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2006; 102:2555-2561.
20. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003; 4:277-289.
21. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313:1785-1787.
22. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106:3058-3061.
23. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006; 94:524-531.
24. Dignat-George F, Sampol J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol 2000; 65:215-220.
25. Woywodt A, Blann AD, Kirsch T, et al. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 2006; 4:671-677.
26. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97:3658-3661.